CO2021004783A1 - Composition of nano-particulate naproxen in vegetable oil useful for the treatment of inflammation and pain - Google Patents

Composition of nano-particulate naproxen in vegetable oil useful for the treatment of inflammation and pain

Info

Publication number
CO2021004783A1
CO2021004783A1 CONC2021/0004783A CO2021004783A CO2021004783A1 CO 2021004783 A1 CO2021004783 A1 CO 2021004783A1 CO 2021004783 A CO2021004783 A CO 2021004783A CO 2021004783 A1 CO2021004783 A1 CO 2021004783A1
Authority
CO
Colombia
Prior art keywords
naproxen
action
composition
active ingredient
particulate
Prior art date
Application number
CONC2021/0004783A
Other languages
Spanish (es)
Inventor
Oscar Alzate
Original Assignee
Oscar Alzate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oscar Alzate filed Critical Oscar Alzate
Priority to CONC2021/0004783A priority Critical patent/CO2021004783A1/en
Priority to PCT/IB2022/053490 priority patent/WO2022219567A1/en
Publication of CO2021004783A1 publication Critical patent/CO2021004783A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El presente desarrollo se refiere a una composición tópica que comprende naproxeno nano-particulado como ingrediente activo, dispuesto sobre un vehículo oleoso que se seleccionade uno o más aceites ricos en terpenoides, y excipientes farmacéuticamente aceptables. Elpresente desarrollo, también se refiere al método para producir dicha composición a travésde las etapas de obtener las nano partículas de naproxeno con un tamaño de partícula entre200 y 300 nm, mezclar las nano partículas con uno o más aceites vegetales ricos enterpenoides, agregar excipientes farmacéuticamente aceptables y opcionalmentecompuestos adicionales como quercetina, isoquercetina, ácido clorogénico, astragalina omezclas de los mismos hasta obtener una mezcla homogénea.La composición desarrollada permite vehiculizar el naproxeno de tal manera que se absorbaa través de la piel de manera efectiva, favoreciendo el efecto analgésico y/o antinflamatoriodel naproxeno, garantizando la entrega del activo en el sitio de acción, disminuyendo eltiempo de acción debido a su aplicación y acción local y disminuyendo o eliminando losefectos gástricos secundarios propios del mecanismo de acción del activo en comparacióncon las composiciones conocidas comercialmente.Página 15 de 15The present development refers to a topical composition comprising nano-particulate naproxen as an active ingredient, placed on an oily vehicle selected from one or more oils rich in terpenoids, and pharmaceutically acceptable excipients. The present development also refers to the method for producing said composition through the steps of obtaining naproxen nanoparticles with a particle size between 200 and 300 nm, mixing the nanoparticles with one or more enterpenoid-rich vegetable oils, adding pharmaceutically acceptable excipients and optionally additional compounds such as quercetin, isoquercetin, chlorogenic acid, astragalin or mixtures thereof until a homogeneous mixture is obtained. anti-inflammatory drug of naproxen, guaranteeing the delivery of the active ingredient to the site of action, reducing the time of action due to its application and local action, and reducing or eliminating the secondary gastric effects typical of the mechanism of action of the active ingredient in comparison with commercially known compositions. Page 15 of 15

CONC2021/0004783A 2021-04-15 2021-04-15 Composition of nano-particulate naproxen in vegetable oil useful for the treatment of inflammation and pain CO2021004783A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CONC2021/0004783A CO2021004783A1 (en) 2021-04-15 2021-04-15 Composition of nano-particulate naproxen in vegetable oil useful for the treatment of inflammation and pain
PCT/IB2022/053490 WO2022219567A1 (en) 2021-04-15 2022-04-13 Nano-particulated naproxen composition in vegetable oil useful for the treatment of inflammation and pain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CONC2021/0004783A CO2021004783A1 (en) 2021-04-15 2021-04-15 Composition of nano-particulate naproxen in vegetable oil useful for the treatment of inflammation and pain

Publications (1)

Publication Number Publication Date
CO2021004783A1 true CO2021004783A1 (en) 2022-10-21

Family

ID=83640527

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0004783A CO2021004783A1 (en) 2021-04-15 2021-04-15 Composition of nano-particulate naproxen in vegetable oil useful for the treatment of inflammation and pain

Country Status (2)

Country Link
CO (1) CO2021004783A1 (en)
WO (1) WO2022219567A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612556D0 (en) * 2006-06-23 2006-08-02 Univ Aston Topical pharmaceutical formulations
CA2646932A1 (en) * 2008-12-10 2010-06-10 Lancelot Biotech Inc. Method for the topical application of a medicinal preparation
US10806790B1 (en) * 2013-11-12 2020-10-20 Scott Shapiro Pain therapy cream with deep tissue delivery system
IN201621029815A (en) * 2016-08-31 2016-09-16 Shripad Abhimanyu PANSARE

Also Published As

Publication number Publication date
WO2022219567A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
AR054064A1 (en) COMPOSITION WITH ACTIVE PHARMACEUTICAL INGREDIENT BASED ON CANABINOID FOR IMPROVED DOSE FORMS
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
ECSP11011278A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES DERIVATIVES OF GLUCOPIRANOSIL DIFENYLMETHANE, PHARMACEUTICAL FORM OF THE SAME, PROCEDURE FOR THEIR PREPARATION AND USES OF THE SAME FOR IMPROVED GLUCEMIC CONTROL IN A PATIENT.
CO2021000174A2 (en) Topical compositions for pain relief
AR048705A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II
CO5640037A2 (en) DERIVATIVES OF QUINAZOLINE FOR THE TREATMENT OF CANCER
CL2020000747A1 (en) Niraparib formulations.
AR065580A1 (en) IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME
AR068820A1 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF VENOTONIC AGENTS AND VASOPROTECTORS FOR THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCY AND USE
NZ600358A (en) Topical foam composition
WO2010089046A1 (en) In situ preparations forming bonding gel, in particular for topical application to moistened skin/mucous membranes
MX2011012982A (en) Topical micro-emulsions for the treatment of rheumatic disorders.
PE20150773A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF PHENYLEPHRINE
CL2017001913A1 (en) Topical curative composition
AR074309A1 (en) ANTI-INFLAMMATORY COMPOUNDS AND THEIR PHARMACEUTICAL, DENTIFRICAL AND ADHESIVE COMPOSITIONS. METHOD
BRPI0506496A8 (en) PHARMACEUTICAL COMPOSITION WITH IMPROVED TOLERANCE AT THE INJECTION SITE COMPRISING SULFOBUTYLETHER-SS-CYCLODEXTRIN AND ITS USE IN THE TREATMENT OF EMESIS INJECTION SITE COMPRISING SULFOBUTYLETHER-SS-CYCLODEXTRIN AND ITS USE IN THE TREATMENT OF EMESIS
CY1123695T1 (en) PHARMACEUTICAL COMPOSITION WITH ANTI-INFLAMMATORY AGENTS AND PROCESS OF PREPARATION
AR065582A1 (en) IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME
CO6640244A2 (en) Topical pharmaceutical compositions
CO2021004783A1 (en) Composition of nano-particulate naproxen in vegetable oil useful for the treatment of inflammation and pain
CO2022003583A2 (en) Curcumin compounds and basic amino acids
AR066666A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVING AGENT
CN111617136A (en) Pain relief formulations and methods of treatment
RU2013105513A (en) Derivatives of 1-aminoalkylcyclohexane for the treatment of inflammatory skin diseases
RU2543326C2 (en) Pharmaceutical composition for treating skin itching